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Abstract: Genetic and non-genetic predictors of 15-year survival
in patients with chronic three-vessel disease (3VD) were investigated.
Coronary angiography was performed on 810 subjects with symp-
toms of stable ischemic heart disease in 1998. The patients with 3VD
were genotyped for 23 candidate polymorphisms covering the PPAR-
RXR pathway, matrix metalloproteinase-2, renin–angiotensin–aldoster-
one system, endothelin-1, cytokine genes, MTHFR and APO E variants.
Fifteen-year survival data were obtained from the national insurance
registry. All data were available in the case of 150 patients with 3VD.
Statistical analysis used stepwise Cox regression with dominant, reces-
sive, or additive mode of genetic expression. Involved variables included
age, sex, BMI, blood pressure, diabetes, ejection fraction, left main
stenosis, previously diagnosed coronary stenosis, myocardial infarction
in personal history, and coronary bypass along with polymorphisms pre-
selected by log-rank tests.
Out of the 23 polymorphisms, four were included in the model
construction. SNP in the IL-6 gene rs1800795 (174 G/C) has been
found to be a significant predictor of survival. This SNP was in a linkage
disequilibrium with rs1800797 (597 G/A) in the same gene (D0 ¼ 1.0),
which was also found to constitute a significant predictor of survival
when rs1800795 was not included in the model construction. Age,
increased BMI, diabetes, low EF, and left main stenosis were alsorgova´, MSc, PhD, , MD, PhD,
nd Anna Vasˇku˚, MD, PhD
as significant independent risk factors for the survival of patients with
three-vessel disease.
(Medicine 93(28):e278)
Abbreviations: ACE = angiotensin converting enzyme, AGT =
angiotensinogen, ApoE = apolipoprotein E, APO E =
apolipoprotein E gene, bp = base pair, BMI = body mass index,
CI = confidence interval, CABG = coronary artery bypass graft,
CAD = coronary artery disease, DM = diabetes mellitus, DBP =
diastolic blood pressure, EF = ejection fraction, ET-1 = endothelin-
1, GWAS = genome-wide association studies, HR = hazard ratio,
IL = interleukin, LAD = left anterior descendent branch, LCx = left
circumflex branch, MMP = matrix metalloproteinase, MTHFR =
methylene tetrahydrofolate reductase, MAF = minor allele
frequency, PCI = percutaneous coronary intervention, PPAR =
peroxisome proliferator-activated receptor, PCR = polymerase
chain reaction, RAAS = renin–angiotensin–aldosterone system,
RXR = retinoid X receptor, RCA = right coronary artery, SNP =
single nucleotide polymorphism, SBP = systolic blood pressure,
3VD = three-vessel disease, TACE = TNF-a converting enzyme,
TNF = tumour necrosis factor.
INTRODUCTION
C oronary artery disease (CAD) and its complications – suchas myocardial infarction or heart failure – is one of the
leading causes of death in most world populations.1,2 Three-
vessel disease (3VD) represents the most severe form of cor-
onary atherosclerosis. Patients with 3VD and/or left main
stenosis are considered a high-risk group according to thera-
peutic guidelines.3 In comparison with less severe forms of
CAD, 3VD has been consistently associated with worse long-
term prognosis.4–7 Genetic variation in several metabolic,
inflammatory, and local signal pathways is worthy of consider-
ation concerning possible effects on patients’ survival.
Overall heritability of CAD has been estimated at approxi-
mately 50% in population studies and over 30 genes have been
associated with CAD onset in genome-wide association studies
(GWAS).8 While the genome-wide association approach
explains only a small fraction of total heritability,9 candidate
gene-based studies often suffer from various types of bias which
may lead to both false positive and false negative results.10–12 The
role of various suspected genetic risk factors in the survival of
patients already suffering from symptomatic CAD is not yet
well understood.
As atherosclerosis is an inflammatory process, cytokines
play an important role in its pathogenesis. Cytokines such as(TNF) a and interleukin (IL) 6 have been
hile TNF-a seems to be clearly pro-
IL-6 is somewhat ambivalent in animal
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and human studies.13 The precursor of TNF-a is converted to its
active form by its converting enzyme, TACE.14 TNF-b, also
known as lymphotoxin a, is secreted by regulatory T-lympho-
cytes and exhibits anti-atherogenic effects.15
Regarding the variation of lipid metabolism pathways, one
of the key molecules is apolipoprotein E (ApoE¼ protein, APO
E¼ gene), a protein which ensures lipoprotein clearance, pre-
vents lipid accumulation in the vessel wall,16 and has antiox-
idant,17 vasodilatory18 and anti-inflammatory19 effects. The
peroxisome proliferator-activated receptor/retinoid X receptor
(PPAR-RXR) pathway is involved in both the regulation of the
lipid and glucose metabolism and in cytokine release.20 The
lower expression of PPAR-g and RXR-a has been associated
with the faster progression of carotic atherosclerosis.21 Sim-
ilarly, PPAR-a also has anti-atherogenic properties22
Contributing to local inflammation, matrix metalloprotei-
nases (MMPs) are endopeptidases which degrade the extra-
cellular matrix. Many MMPs are expressed in atherosclerotic
vessels.23,24 Of these, MMP-2 has been found to participate in
lesion formation in the animal model of atherosclerosis25 and its
gene expression is higher in acute coronary syndrome patients
compared to healthy subjects.26
The renin–angiotensin–aldosterone system (RAAS) plays
also role in tissue remodelling and is an important regulator of
blood pressure. The hyperactivity of RAAS is linked to cardi-
ovascular diseases including hypertension and CAD. Angio-
tensin converting enzyme (ACE) is a key molecule activating
angiotensin II, which is a strong vasoconstrictor.27 Endothelins
are a group of other vasoconstriction peptides. Endothelin-1
(ET-1) is synthesized mostly in the vessel wall and is the most
potent vasoconstrictor. Moreover, it exerts several other bio-
logical functions leading to elevated blood pressure.28
From other possible risk-modifying factors, methylene
tetrahydrofolate reductase (MTHFR) is an enzyme important
for homocysteine degradation. The overaccumulation of homo-
cysteine is associated with higher risk of atherosclerosis, prob-
ably through various mechanisms.29
We conducted the study to establish the genetic and other
factors contributing to all-cause death of patients with chronic
symptomatic 3VD. The aim was to create a model predicting
patients’ survival based on significant and independent risk
factors. The non-genetic determinants that were considered to
possibly play an important role in survival included the follow-
ing clinical factors and characteristics of cardiac involvement:
age at admission, sex, body mass index (BMI), systolic and
diastolic blood pressure (SBP and DBP, respectively), diabetes
mellitus (DM), hyperlipidemia, ejection fraction (EF), left main
stenosis, extent of CAD, previously diagnosed stenosis of
coronary artery, myocardial infarction in personal history,
and mode of intervention – coronary artery bypass grafting
(CABG), percutaneous coronary intervention (PCI), or pharma-
cological therapy. Potential genetic factors involved 23 candi-
date polymorphisms including the variants in genes coding
RXR-a, RXR-b, PPAR-a, PPAR-g, endothelin-1, TNF-a, TA-
CE, TNF-b, IL-6, MMP-2, angiotensinogen (AGT), ACE,
MTHFR, and ApoE.
METHODS
Coronary Angiography and Patient Selection
Ma´chal et alLeft and right coronary angiography and left ventriculo-
graphy were performed on 810 consecutive subjects at the First
Department of Internal Medicine – Cardioangiology at St.
2 | www.md-journal.comAnne’s University Hospital in Brno in 1998. The subjects
suffered from chest pain or other symptoms of stable ischemic
heart disease. Coronary angiograms were assessed by four
experienced invasive cardiologists. Of the total number of
subjects, 196 suffered from 3VD, defined as 50% stenosis
of the left anterior descendent branch (LAD), left circumflex
branch (LCx), right coronary artery (RCA), and/or major
branches of each artery. Extent of CAD was defined as the
number of segments with 50% stenosis, according to the
16-segment scheme of American Heart Association.
Informed consent was obtained from all patients prior to
their recruitment according to the requirements of Ethics com-
mittee of St. Anne’s University Hospital, which approved the
study. All the procedures were in accord with the Helsinki
Declaration of 1975 as revised in 1983. Patients treated for
concomitant significant valvular disease and those after heart
transplantation were excluded. The remaining subjects were
genotyped for 23 candidate polymorphisms and other clinical
and laboratory data were collected. Data about 15-year survival
were obtained from national insurance registry on May 23,
2013. All data were available in the case of 150 patients; only
these subjects were included in subsequent analyses. The
reasons of the exclusion of remaining 46 patients were incom-
plete genetic analysis of 23 polymorphisms (n¼ 40), incom-
plete clinical data (n¼ 5), and inability to obtain the data about
patients survival from national insurance registry (n¼ 1). There
was no difference in survival between patients included and
excluded in the model (in case when survival data were avail-
able; Gehan Wilcoxon test P-value¼ .28).
Laboratory Methods
DNAwas extracted from peripheral blood leukocytes using
the phenol–chloroform method. Of the total number of 23 poly-
morphisms, 21 were identified using polymerase chain reaction
(PCR), and restriction analysis. For the single nucleotide poly-
morphism (SNP) rs1536475 (intron 7, þ70 A/G) in the RXR-a
gene, PCR was carried out in a volume of 25ml, containing 0.8U
of Taq polymerase and primers 5-AGACAGCTGAGTGAC
TGTGTG C-3 (forward) and 5-GAAATAATACTAGGCAGG
ATGTGC-3 (reverse). The method was described in30 and the
resulting fragment was 269 base pairs (bp) in length. The process
of restriction analysis was modified in our laboratory and inclu-
ded digestion by SatI enzyme in 378C and electrophoresis in 2%
agarose gel (Serva). The resulting fragments were 162þ 66þ
41 bp (A allele) or 123þ 66þ 41þ 39bp (G allele) in length.
The parameters of methods used in the detection of other
polymorphisms have been described in our previous publi-
cations. This includes polymorphisms rs148360070 (intron 5
39526 A/AA) and rs1805343 (intron 9 25 G/A) in the RXR-a
gene and all variants in genes coding RXR-b,31 PPAR-a, PPAR-
g,32 endothelin-1, TNF-a, TACE, TNF-b,33 IL-6,34,35 MMP-
2,36 angiotensinogen,37 ACE,38 and MTHFR.39
Two polymorphisms in the Apo E were determined using
real-time PCR monitored by SYBR Green.40 The method was
optimized by our research group.41
Statistical Analysis
The Cox regression model was used in order to estimate the
contribution of genetic polymorphisms and other risk factors to
overall survival. The genetic variants had been pre-selected out
Medicine  Volume 93, Number 28, December 2014of the total number of 23 polymorphisms in candidate genes
using the Kaplan–Meier method and log-rank tests in dominant,
recessive and co-dominant modes of allelic expression. A
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TABLE 1. Basic Characteristics of the Subjects
Total/men 150/121
Age at admission (years)y 63.5 (54.9–70.2)
BMI (kg m2) 27.2 3.4
Systolic blood pressure (mm Hg)y 140 (130–155)
Diastolic blood pressure (mm Hg)y 80 (80–90)
Antihypertensive medication (n/% of total) 140/93.3%
ACE inhibitors 50.0%
beta-blockers 83.0%
calcium channel blockers 22.3%
diuretics 23.7%
Cholesterol (mmol/l) 5.85 1.18
Triacylglycerols (mmol/l)y 1.72 (1.29–2.37)
Hyperlipidemia (n/% of total) 47/31.3%
Hypolipidemic medication (n/% of total) 82/54.7%
statins 43.7%
fibrates 11.7%
Glycemia (mmol/l)y 5.5 (3.9–6.3)
Diabetes mellitus (n/% of total) 41/27.3%
Antidiabetic medication (n/% of total) 28/18.7%
oral 16.3%
insulin 4.0%
Ejection fraction (%) 48% (40–60%)
Involved coronary segments yy (n)y 5 (4–6)
y Parameters with non-normal distribution marked by a dagger are
expressed as median (lower–upper quartile). Parameters with normal
distribution are expressed as mean standard deviation.
yy Segments with 50% stenosis, according to the 16-segment
scheme of American Heart Association.
Patients With Chronic 3VD in a 15-Year Follow-Up StudyP-value of .1 was used as the cut-off for including the variable in
the Cox regression analysis, the power of log-rank tests were 0.2
to 0.8 for each separate test, depending on allele and genotype
frequency. Tests with lower power due to low number in one of
the compared groups were not performed; the combination of
three tests for each polymorphism increased power to at least
0.6 with the exception of APO E2. The Hardy–Weinberg
equilibrium was calculated for each polymorphism using the
x2-test. To address potential selection bias, the log-rank tests
were repeated for the variants included in the Cox regression
model construction in all patients with 3VD, where the data
about given variant and survival were available (150< n< 196).
A stepwise construction of the Cox regression model with
a P-value to include of .05 and P-value to remove of .051 was
subsequently employed to determine the contribution of pre-
selected genetic and other variables to overall survival. Non-
genetic variables included in the stepwise construction were age
at admission, sex, BMI, hyperlipidemia, systolic and diastolic
blood pressure, DM, EF, left main stenosis, extent of CAD,
previously diagnosed stenosis of coronary artery, myocardial
infarction in personal history, and mode of treatment.
With the unknown allelic coefficient of dominance, three
models of gene expressions were employed: dominant, where
minor allele carriers were compared with major allele homo-
zygotes, recessive, where major allele carriers were compared
with minor allele homozygotes (calculated only when the
number of minor allele homozygotes was more than five)
and additive, a gene dose-based model where the values 0, 1
and 2 were attributed to major allele homozygotes, heterozy-
gotes, and minor allele homozygotes.
Finally, an all-effects multivariate Cox model was used to
determine the hazard ratio (HR) with 95% confidence interval
(CI) of different genotypes of the SNPs determined as a
significant factor in overall survival following adjustments
for age, sex, body mass index (BMI), systolic and diastolic
blood pressure (SBP and DBP, respectively), diabetes mellitus
(DM), hyperlipidemia, left main stenosis, EF, extent of CAD,
previously diagnosed stenosis of coronary artery, myocardial
infarction in personal history, and mode of treatment. Bonfer-
roni correction was used for multiple comparisons testing, the
respective P-values are listed as pcorr. Comparisons of continu-
ous variables between specified groups of patients were per-
formed using Mann–Whitney U-test; for categorical variables
Fisher exact test was used. Generally, a¼ 0.05 was used to
determine statistically significant results in all analyses. STA-
TISTICA software (StatSoft, version 12) was used for statistical
analysis. MIDAS software (version 1.0)42 was used for linkage
disequilibrium determination.
RESULTS
The basic characteristics of the group and its medication
are shown in a table (Table 1). Approximately 50% of the
patients with three-vessel disease died before the end of the
study. The 5-year survival rate was 88%.
The pre-selection of polymorphisms included in final model
construction was based on log-rank P-values. Only the genetic
variants with P< .10 in at least one model were selected for
further analysis (Table 2). Polymorphisms rs1536475 in RXR-a,
1800629 in TNF-a, and two SNPs in Il-6 (rs1800795 and
1800797) met the inclusion criteria. When the log-rank tests
Medicine  Volume 93, Number 28, December 2014were repeated in all patients with 3VD where the data about given
variant and survival were available, only the two latter poly-
morphisms showed the P-value <.10 (and <.05, actually).
# 2014 Lippincott Williams & WilkinsThe stepwise Cox regression model construction identified
the same significant predictors of survival consistently in
all three models: age at admission, ejection fraction, left
main stenosis, BMI, diabetes, and polymorphism rs1800795
(174 G/C) in the IL-6 gene. In additive model, the effect of
rs1800795 alleles remained significant after Bonferroni correc-
tion, the C allele was associated with worse prognosis. This SNP
was in strong linkage disequilibrium with rs1800797 (597 G/
A) in the same gene (D0 ¼ 1.0; r2¼ .97; P< 1020). The G–G
haplotype was the most common (51%), followed by A–C
(48%) and G–C (1%); A–G was missing in our group of
patients. SNP rs1800797 was also a significant predictor of
survival in the additive model when rs1800795 was not included
in model construction. The G allele was protective and the A
allele risky in this case. No other polymorphism was a signifi-
cant independent predictor of survival (Table 3).
The final multivariate model obtained by stepwise Cox
regression and including all significant predictors (with the
additive effect of rs1800795 alleles) is shown in a table
(Table 4).
Following adjustments for all clinical covariates (all
effects model) and compared to GG carriers of rs1800795,
CG carriers had a HR of 2.19 (95% CI¼ 1.05–4.58) and CC
homozygotes had a HR of 3.79 (95% CI¼ 1.78–8.10). The
Kaplan–Meier survival curves of different genotypes of
rs1800795 following adjustment for age, sex, diabetes, BMI,
EF, extent of CAD, dyslipidemia, SBP, DBP, left main stenosis,
previously diagnosed coronary stenosis, myocardial infarction
in personal history, and mode of intervention are shown in a
www.md-journal.com | 3
TABLE 2. Candidate Polymorphisms, Their Respective Minor Allele Frequencies (MAF) and Log-Rank P-Values. Polymorphisms
Included in the Stepwise Cox Regression Model Construction are Indicated in Bold Italics
Polymorphism rs MAF Overall Dominant Recessive
RXRa intron 5 I/D (39526 AA/A) rs148360070 D>I; 0.09 0.396 0.443 –
RXRa intron 7 R70 A/G rs1536475 G>A; 0.19 0.092 0.059 0.609
RXRa intron 9 25 G/A rs1805343 A>G; 0.34 0.208 0.395 0.511
RXRb 30 þ140 A/T rs2072915 A>T; 0.36 0.892 0.598 0.856
RXRb 30 þ7 G/T rs2744537 G>T; 0.29 0.510 0.683 0.322
PPARg 161 C/T rs3856806 C>T; 0.17 0.261 0.332 –
PPARa L162V (484 C/G) rs1800206 C>G; 0.08 0.809 0.833 –
MMP2 790 T/G rs243864 T>G; 0.22 0.546 0.345 –
MMP2 735 C/T rs2285053 C>T; 0.13 0.640 0.993 –
MMP2 1306 C/T rs243865 C>T; 0.21 0.619 0.413 –
MMP2 1575 G/A rs243866 G>A; 0.22 0.539 0.330 –
ACE I/D rs1799752 D>I; 0.49 0.342 0.294 0.682
AGT 6A/G rs5051 G>A; 0.45 0.900 0.759 0.705
AGT M235T (T/C) rs699 T>C; 0.46 0.832 0.669 0.813
Endothelin 8002 G/A rs2071942 G>A; 0.20 0.193 0.790 0.138
TNFa (S308 G/A) rs1800629 G>A; 0.13 0.098 0.082 –
TNFb B1/B2 (þ252 G/A) rs909253 G>A; 0.31 0.184 0.157 0.514
TACE 30 2712 G/A rs6705408 G>A; 0.42 0.464 0.470 0.502
IL-6 S597 G/A rs1800797 G>A; 0.48 0.049 0.022 0.043
IL-6 S174 G/C rs1800795 G>C; 0.49 0.033 0.015 0.028
MTHFR rs1801133 C>T; 0.35 0.726 0.372 0.916
APO E4 rs429358 C>T; 0.13 0.886 0.536 –
C>
Ma´chal et al Medicine  Volume 93, Number 28, December 2014graph (Figure 1). Analogically, compared to GG homozygotes
in rs1800797, AG heterozygotes had a HR of 2.09 (95%
CI¼ 1.01–4.33) and AA homozygotes exhibited a HR of
3.40 (95% CI¼ 1.61–7.16); a P-value was<.05 in all the cases.
Of the total number of 150 patients, a majority (n¼ 94) was
treated by CABG, 28 patients underwent PCI, and the remaining
subjects (n¼ 28) were treated pharmacologically. The CABG
procedure was not a significant independent predictor of survival
in the stepwise Cox regression model. In a separate analysis,
CABG was superior to pharmacological therapy (log-rank test:
APO E2 rs7412P¼ .04); however, this effect became insignificant in a multi-
variate model (P¼ .18, HR¼ 0.65, 95% CI¼ 0.35–1.21) follow-
ing adjustment for all clinical covariates. Patients treated by
TABLE 3. Effect of Selected Polymorphisms in Multivariate Anal
Significant Independent Predictors of Survival. The Major Allele W
Polymorphism
Dominant Model
HR (95% CI) P-Value
RXRa intron 7 þ70 A/G (rs1536475)
G>A
NS NS
TNFa 308 G/A (rs1800629) G>A NS NS
IL-6 174 C/G (rs1800795) G>C 2.13 (1.15–3.96) 0.017
IL-6 597 A/G (rs1800797) G>A NS NS
yHazard ratios are per one allele.
pcorr¼ non-significant (NS).
pcorr¼ 9 103.
Assuming rs1800795 was not included in model construction; pcorr¼
4 | www.md-journal.comCABG had higher EF compared to patients treated by PCI or
pharmacological therapy (P¼ 6 103), they did not differ in
other investigated clinical parameters and characteristics of
cardiac involvement.
DISCUSSION
Clinical and Angiographic Predictors of Mortality
This study revealed several significant independent predic-
tors of mortality in patients with chronic 3VD. Characteristics of
T; 0.03 0.464 0.395 –cardiac involvement, detected using coronary angiography, and
ventriculography were important predictors of all-cause death.
Specifically, left main stenosis increased the risk of death more
ysis. P-Values and Hazard Ratios (HR) are Adjusted for Other
as Taken as the Reference Variant
Recessive Model Additive Modely
HR (95% CI) P-Value HR (95% CI) P-Value
NS NS NS NS
NS NS NS NS
1.89 (1.11–3.21) 0.018

1.68

(1.19–2.37) 3 103
NS NS 1.60

(1.13–2.25) 4 103
0.012.
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TABLE 4. Final Multivariate Cox Regression Model Including All Significant Independent Predictors of Survival
Factor P-value HR (95% CI)
EF 4 105 0.79 (0.71–0.89) per each 5%
Age at admission 9 105 1.76 (1.33–2.34) per 10 years
Left main stenosis 3 104 3.36 (1.74–6.50)
IL-6 174 C/G (rs1800795) G>Cy 3 103 1.68 (1.19–2.37) per each C allele
BMI 4 103 1.12 (1.04–1.21) per 1 kg m2
23
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by approximately 20%. Other significant predictors of death –
age, diabetes, and BMI – are considered to be established
cardiovascular risk factors.43–45 Diabetes mellitus leads to hyper-
glycaemia which promotes the progression of atherosclerosis
both directly, by non-enzymatic glycation of endothelial
proteins,46 and indirectly, by lipoprotein modification and
changes in their function.47–49
In this study, higher BMI was associated with a worse
prognosis in multivariate analysis: an increase of 1 kg m2
increased risk of death by over 12%. This result confirms the
role of overweight as an independent risk factor in patients
suffering from 3VD and is in contradiction with some studies
and meta-analyses reporting on the so-called ‘‘obesity paradox,’’
that is, better prognosis in overweight cardiac patients.50,51
However, selection bias is most likely at least a component factor
contributing to the obesity paradox.52 It must be noted that the
study group assembled for the purposes of our study was rela-
tively homogenous and that patients suffered from a severe form
of coronary atherosclerosis. Prospective design, as used in our
study, should reduce the possibility of selection bias which might
influence the results of retrospective studies.
Diabetes 0.0
yAdditive effect of rs1800795 alleles.Promoter Polymorphisms in Interleukin 6 Gene
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FIGURE 1. Effect of rs1800795 (174 G/C) in the IL-6 gene on
survival inmultivariate analysis. Kaplan–Meier curves are adjusted for
age, sex, diabetes, BMI, EF, SBP, DBP, left main stenosis, previously
diagnosed coronary stenosis and myocardial infarction in personal
history. Compared to GG homozygotes, both CG (HR¼2.19; 95%
CI¼1.05–4.58; P¼ .04) and CC (HR¼3.79; 95% CI¼1.78–8.10;
P¼6104) carriers showed higher mortality.
# 2014 Lippincott Williams & WilkinsOut of the 23 potential genetic predictors (including
genetic variants of the PPAR-RXR pathway, matrix metallo-
proteinase-2, renin–angiotensin–aldosterone system, endothe-
lin-1, cytokine genes, MTHFR and APO E), only two closely
linked polymorphisms in the IL-6 promoter proved to have both
statistical and clinical significance for patient survival. The role
of IL-6 and its genetic variants in atherosclerosis is not fully
clarified and results of many in vitro, animal model and human
studies are controversial. In vitro, IL-6 stimulates angiogen-
esis53 while animal models of atherosclerosis have shown IL-6
to be both anti-atherosclerotic54,55 and pro-atherosclerotic,56
depending on concentration. It has also been found to have pro-
coagulation and pro-inflammatory effects57,58 and to contribute
to heart remodelling after myocardial infarction in human
patients.59 The long-term elevation of IL-6 levels has been
associated with the risk of CAD60 and CAD severity.61 Elevated
concentrations of IL-6 are also predictors of mortality in
patients with CAD or heart failure,62,63 although the causality
is uncertain and the concentration of IL-6 largely varies in the
same individual.64 ‘‘Trans-signalling,’’ that is, cell activation
by the soluble IL-6/IL-6 receptor complex instead of more
specific IL-6 binding to its surface receptor, is probably respon-
sible for many detrimental effects of IL-6.65,66
The promoter polymorphisms of IL-6 have been repeat-
edly associated with different gene expression. The promoter
region from225 to113, that is, involving the common174
G/C polymorphism, contains regulatory elements which ensure
transcription induction by IL-1 or TNFa.67 Indeed, following
stimulation by IL-1, transcription is enhanced in the IL-6 174
G-allele containing transfected HeLa cells when compared to
the C-allele; this SNP can therefore be considered functional.68
The carriers of different genotypes have different plasmatic
concentration of IL-6, which decreases in a sequence of
GG>GC>CC in healthy people68 or in patients with brain
vessel malformations,69 while CC carriers were shown to have
higher IL-6 levels in days following coronary artery bypass
graft surgery, suggesting a different pattern during inflamma-
tory responses.70 This effect may be partially explained by
linkage disequilibrium with another functional promoter SNP in
the IL-6 gene, that is,6331 T/C, located in the binding site for
enhancing transcription factor Oct-1.71 Other polymorphisms in
the IL-6 gene have also been shown to influence its expression
in interaction with 174 G/C. They include 597 G/A, SNP in
strong linkage disequilibrium with 174 G/C, which was
confirmed in our study.72,73 Following the administration of
lipopolysaccharides, bacterial surface molecules capable of
1.85 (1.09–3.16)inducing foam cell formation,74 a lower secretion of IL-6
was observed in subjects with 597 G to 174 G haplotypes
compared to 597 A to 174 C haplotypes.73
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The relationship between IL-6 polymorphisms and CAD
has been investigated for more than 20 years and may provide
insight into causality in the association between high IL-6 levels
and CAD. In a recent extensive meta-analysis of 50 studies
involving over 30,000 patients, no significant association
between IL-6 174 G/C and coronary artery disease onset
was established in patients of Caucasian origin. However, there
was substantial heterogeneity among the studies. In subgroup
analysis the G allele was protective in studies where population-
based control subjects were used and in non-Caucasian popu-
lations.75 Data regarding survival of patients with confirmed
CAD are scarcer. In patients presenting with acute coronary
syndrome, the G allele was found to have detrimental effects on
1-year survival.76 On the other hand, in another study including
218 patients with chronic CAD and renal failure, subjects
carrying the G allele had a significantly better prognosis which
was found to be consistent with our results.77 It is possible that
mildly elevated IL-6 levels in 597 G to 174 G carriers could
be beneficial due to their support of angiogenesis in chronic
3VD, while the increased risk of plaque destabilization is more
important after acute coronary syndrome.
Other Investigated Polymorphisms
In the present study, none of the remaining 21 investigated
polymorphisms constituted significant independent risk factors
of death in patients suffering from 3VD, although the associ-
ation with CAD has been previously reported in many cases. For
example, promoter polymorphisms of the MMP-2 gene 1306
C/T and 790 T/G have been associated with the presence of
CAD in a meta-analysis of 9 studies78 including a study
conducted by our research group which compared patients with
3VD to controls.36 The genetic variation of RAAS has also been
extensively studied in cardiovascular research. Polymorphisms
of ACE and angiotensinogen have been associated with differ-
ent angiotensin II levels, as well as with cardiovascular risk.79 A
common polymorphism in MTHFR, 677 C/T, has been associ-
ated with the risk of atherosclerosis in Asian populations. In
Europeans, who have a relatively higher folate intake, no
significant contribution of MTHFR 677 C/T to the onset of
CAD has been established80; however, there might be greater
risk for the T allele in otherwise risky subgroups.81 The intron
polymorphism of the ET-1 gene 8002 G/A has been associated
with myocardial infarction by our group.33 In our previous
research we failed to prove the effect of polymorphisms in
PPAR-a PPAR-g and RXR-a on prognosis after PCI32; how-
ever, variation in the RXR-a intron was associated with all-
cause heart failure.82 Furthermore, 161 C/T in PPAR-g has been
linked to CAD among the Chinese (but not Caucasians) in a
recent meta-analysis.83
The APO E locus belongs to 35 loci which have been
associated with CAD in GWAS.8 While e4 carriers are at a
slightly higher risk of atherosclerosis compared to most fre-
quent e3/e3 homozygotes, the e2 allele is protective in hetero-
zygotes and e2/e2 homozygotes have a variable risk of
atherosclerosis.84 With respect to tumour necrosis factors,
association studies of TNF-a promoter variants have produced
various results85–87 while the role of polymorphism B1/B2
(þ252 G/A) in TNF-b, previously suggested as contributing
to CAD onset, was found to be insignificant in a meta-analysis
of 22 studies.88
Ma´chal et alSince data from other studies regarding the effect of the
mentioned variants on CAD patient survival are largely missing,
this study contributes to understanding their role in the
6 | www.md-journal.comprogression of atherosclerosis. The long-term prospective
approach should be a useful tool with respect to the evaluation
of the contribution of these variants to the prognosis of patients
suffering from severe CAD. In our study, only the genetic
variation of the IL-6 promoter added new, independent infor-
mation besides the characteristics of cardiac involvement and
the traditional cardiovascular risk factors.
Limitations
The study has several limitations. Firstly, all patients were
enrolled in single institution, which limits the generalizability of
our results. Other limitation is relatively low number of partici-
pants with all available data which reduces the power of the
study; however the power is gained by relative homogeneity of
the study group and long follow-up time. The power could have
not been high enough to detect all potential genetic and non-
genetic effects and larger multicentre studies are needed in this
respect. The disappearance of the CABG effect in a multivariate
model suggests the role of patient selection for the surgery; in
subsequent analysis, patients with higher EF were more fre-
quently selected for CABG, and EF was the most significant
predictor of survival in stepwise model. However, the fact that
CABG was not a significant independent predictor does not
contradict the established therapeutic benefit of the procedure;
it is rather a consequence of the small size of the PCI and
pharmacological treatment groups, and therefore low power of
the test.
CONCLUSION
Age, increased BMI, diabetes, low ejection fraction, left
main stenosis, and genetic variation in the IL-6 promoter were
established as significant independent risk factors for the sur-
vival of patients with three-vessel disease. The G alleles of
promoter polymorphisms rs1800795 (174 G/C) and
rs1800797 (597 G/A) were associated with lower mortality.
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